These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics. Kaufer D; Gandy S Neurology; 2009 Dec; 73(24):2052-3. PubMed ID: 19923549 [No Abstract] [Full Text] [Related]
4. Failed Alzheimer's trial does not kill leading theory of disease. Abbott A; Dolgin E Nature; 2016 Nov; 540(7631):15-16. PubMed ID: 27905452 [No Abstract] [Full Text] [Related]
5. GlaxoSmithKline cancer drug threatens Herceptin market. Waltz E Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273 [No Abstract] [Full Text] [Related]
6. Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease. Rabinovici GD; La Joie R JAMA; 2023 Aug; 330(6):507-509. PubMed ID: 37459124 [No Abstract] [Full Text] [Related]
7. Deal watch : BMS acquires rights for IL-6 inhibitor. Nat Rev Drug Discov; 2010 Jan; 9(1):10. PubMed ID: 20043020 [No Abstract] [Full Text] [Related]
8. PHARMAC responds on Herceptin assumptions and decisions. Metcalfe S; Evans J N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504 [No Abstract] [Full Text] [Related]
9. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853 [TBL] [Abstract][Full Text] [Related]
10. Genentech's Alzheimer's antibody trial to study disease prevention. Garber K Nat Biotechnol; 2012 Aug; 30(8):731-2. PubMed ID: 22871696 [No Abstract] [Full Text] [Related]